Tag: Warburg Effect
Novel pH Mechanism may Enhance On-Target Effects with Reduced Off-Tumor Toxicity
The development of antibody-based immunotherapies has, compared with conventional therapeutic strategies patients, transformed the therapeutic landscape in melanoma, non-small cell lung cancer, bladder cancer,...
BioAtla Raises $72.5 Million In Series D Financing to Advance CAB-AXL...
San Diego (California-) based BioAtla, a global clinical-stage biotechnology company developing Conditionally Active Biologic antibody therapeutics, confirmed that it has raised $72.5 million in...
First Patient Dosed with AXL-targeted Antibody-drug Conjugate
A first patient has been dosed with BioAtla's BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC). The multi-center, open-label, Phase I/II study called in...
